Sarepta Therapeutics Stock Soars on FDA Approval

Sarepta Therapeutics $167.85 +44.35 (+35.91$55.25 $173.25 P/E Ratio 1,525.91 Price Target$164.00 Add to Watchlist Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. This pivotal decision marks a turning point in treating this debilitating disease and underscores Sarepta ...